Moderna Inc
$ 49.91
0.54%
12 Jun - close price
- Market Cap 19,696,470,000 USD
- Current Price $ 49.91
- High / Low $ 51.75 / 49.62
- Stock P/E N/A
- Book Value 18.66
- EPS -8.14
- Next Earning Report 2026-07-31
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.37 %
- 52 Week High 59.55
- 52 Week Low 22.28
About
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$43.30
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-01 | 2026-02-13 | 2025-11-06 | 2025-08-01 | 2025-05-01 | 2025-02-14 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -3.4 | -2.11 | -0.51 | -2.13 | -2.52 | -2.91 | 0.03 | -3.33 | -3.07 | 0.55 | -9.53 | -3.62 |
| Estimated EPS | -2.11 | -2.6 | -2.16 | -2.97 | -3.11 | -2.7599 | -1.9 | -3.36 | -3.55 | -0.97 | -2.05 | -4.12 |
| Surprise | -1.29 | 0.49 | 1.65 | 0.84 | 0.59 | -0.1501 | 1.93 | 0.03 | 0.48 | 1.52 | -7.48 | 0.5 |
| Surprise Percentage | -61.1374% | 18.8462% | 76.3889% | 28.2828% | 18.9711% | -5.4386% | 101.5789% | 0.8929% | 13.5211% | 156.701% | -364.878% | 12.1359% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-31 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -2.09 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MRNA
2026-06-13 03:08:09
This article analyzes Moderna Inc. (MRNA) using AI models to provide trading strategies based on liquidity mapping. It identifies weak near-term sentiment but strong long-term potential, suggesting choppy conditions ahead. The report offers specific entry and exit points for position trading, momentum breakouts, and risk hedging strategies, relying on multi-timeframe signal analysis.
2026-06-12 18:37:58
This article provides a financial overview of Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs (BCBA:MRNA.CI), specifically focusing on its asset turnover. It presents financial data for different periods, indicating its performance on the Buenos Aires Stock Exchange. The information is sourced from financial data providers like ICE Data Services and FactSet.
2026-06-12 15:37:57
This article provides a revenue breakdown for Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs (BCBA:MRNA.CI), highlighting its financial performance. The primary revenue contribution comes from the United States, which accounted for ARS 1.49 trillion last year, a slight decrease from ARS 1.63 trillion the previous year. The data is presented through TradingView, referencing various financial and market data providers.
2026-06-12 08:54:57
SmartHarvest Portfolios LLC has acquired 9,927 shares of AbbVie Inc. (NYSE:ABBV), valued at approximately $2.27 million, making it their 18th largest holding. This move is part of a broader trend of institutional investors like Vanguard, Geode Capital Management, and Norges Bank increasing their stakes in AbbVie, bringing total institutional ownership to over 70%. Despite a recent FDA Complete Response Letter for TrenibotE due to manufacturing issues, analyst sentiment remains largely positive, citing strong growth drivers in Skyrizi and Rinvoq and several price target increases.
2026-06-12 07:39:38
Argenx SE, a European biotech company, is under investor scrutiny due to its growing autoimmune-drug sales despite broader sector valuation pressures. The company's stock trades below its 52-week high, reflecting sector-wide headwinds like higher interest rates and a shift away from growth-oriented biotechs. Argenx is positioned as a diversified biotech, with its commercial autoimmune franchise and pipeline providing a more stable growth story compared to some other volatile biotech firms.
2026-06-11 21:31:11
Moderna (NASDAQ: MRNA) shares rose nearly 8% following a strong Nasdaq recovery, closing at $49.64. The bounce occurred amidst positive market sentiment and without specific company news, though investor focus remains on Moderna's mRNA cancer vaccine pipeline, particularly after UK regulators approved a new trial for its experimental mRNA-4194 in Lynch syndrome patients. Despite the stock's gains, analysts generally maintain a "Hold" rating with an average target price below the current close.
